NeuroMetrix, Inc. Overview
Pro stress-test →NeuroMetrix develops and commercializes non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The company specializes in neurostimulation-based medical devices designed to address chronic pain and diabetes complications. However, the company was acquired by electroCore in (May 2025) and is no longer independently traded.
Strategic Profile
Pro stress-test →Quell® Fibromyalgia showed sequential revenue growth with significant gains in unique prescribers and prescriptions, demonstrating success in its flagship pain management product. The company's Quell® technology received FDA Breakthrough Designation for reducing moderate to severe symptoms of chemotherapy induced peripheral neuropathy. Prior to acquisition, the company was transitioning to a leaner operational model with reduced expenses.
Competitive Landscape
Pro stress-test →NeuroMetrix specializes in neurostimulation-based medical devices designed to address chronic pain and diabetes complications. The company competes in the wearable neurostimulation and diagnostic pain-management device markets against larger established medical device manufacturers.
Industry Context
NeuroMetrix, Inc. operates in Medical Devices / Bioelectronic Medicine.
Key facts
Founded: 1996 · Headquarters: Woburn, US · Revenue: $1.1M (Q1 2024) · Market cap: $8.9M